Exploration of Phase 3 Data: Superior & Significant Efficacy Challenging Approved Therapies
Time: 9:30 am
day: Day One
Details:
- Measuring efficacy: Discover how therapeutic effects on biomarkers linked to core immuno-derm disease (eg. skin lesions, itch, sleep, and quality of life) are measured
- Documenting durability of response for multiple indications through inhibition of cytokine signalling
